Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gossamer Bio (GOSS) EBIT: 2018-2024

Historic EBIT for Gossamer Bio (GOSS) over the last 7 years, with Dec 2024 value amounting to -$59.9 million.

  • Gossamer Bio's EBIT fell 44.80% to -$49.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$160.8 million, marking a year-over-year decrease of 120.85%. This contributed to the annual value of -$59.9 million for FY2024, which is 67.39% up from last year.
  • Per Gossamer Bio's latest filing, its EBIT stood at -$59.9 million for FY2024, which was up 67.39% from -$183.8 million recorded in FY2023.
  • Over the past 5 years, Gossamer Bio's EBIT peaked at -$59.9 million during FY2024, and registered a low of -$234.0 million during FY2020.
  • In the last 3 years, Gossamer Bio's EBIT had a median value of -$183.8 million in 2023 and averaged -$154.1 million.
  • As far as peak fluctuations go, Gossamer Bio's EBIT fell by 25.69% in 2020, and later soared by 67.39% in 2024.
  • Over the past 5 years, Gossamer Bio's EBIT (Yearly) stood at -$234.0 million in 2020, then rose by 7.62% to -$216.1 million in 2021, then declined by 1.14% to -$218.6 million in 2022, then rose by 15.94% to -$183.8 million in 2023, then surged by 67.39% to -$59.9 million in 2024.